Gilead Sciences, Inc. (Nasdaq:GILD) today announced results of a Phase I/II dose-escalation study of GS 9137, or JTK-303, a novel oral HIV integrase inhibitor. The data, presented this week at the 13th Conference on Retroviruses and Opportunistic Infections (CROI) by Edwin DeJesus, MD, FACP, Medical Director, Orlando Immunology Center (Abstract #J-1011, Late Breaker #160LB), show significant reductions in viral load among HIV-positive patients receiving GS 9137 as monotherapy or in combination with ritonavir as a boosting agent, compared to placebo.
